Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly.


We spend a lot of time discussing the legality of HIMS current FDA strategy and how/if HIMS can compete in a world with increasing competition from players like Function Health and Superpower.

This is not financial advice.

www.xeiavp.com

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Brom Rector and Sam Tabone. Innehållet i podden är skapat av Brom Rector and Sam Tabone och inte av, eller tillsammans med, Poddtoppen.